BCRX
NASDAQBioCryst Pharmaceuticals Inc.
Price$9.14+0.21 (+2.41%)
01:30 PM07:45 PM
News · 26 weeks65+33%
2025-12-282026-06-21
Mix3790d
- Insider18(49%)
- Other9(24%)
- SEC Filings7(19%)
- Earnings2(5%)
- Leadership1(3%)
Latest news
25 items- INSIDERDirector Milne Jill C. was granted 15,294 shares, increasing direct ownership by 92% to 31,938 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Galson Steven K was granted 15,294 shares, increasing direct ownership by 122% to 27,794 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Levin Alan G was granted 15,294 shares, increasing direct ownership by 24% to 79,565 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Frank Steven was granted 15,294 shares, increasing direct ownership by 76% to 35,459 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Sanders Machelle was granted 15,294 shares, increasing direct ownership by 50% to 45,936 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Milano Vincent was granted 15,294 shares, increasing direct ownership by 16% to 108,483 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Stonehouse Jon P was granted 15,294 shares, increasing direct ownership by 1% to 1,339,775 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Mckee Amy E was granted 15,294 shares, increasing direct ownership by 48% to 47,177 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Heggie Theresa was granted 15,294 shares, increasing direct ownership by 23% to 80,646 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- SECBioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)
- PRBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted nine newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 80,650 shares, of BioCryst common stock. The options and RSUs were granted as of June 1, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $8.57 per share, which is equal to the closing price of B
- INSIDERDirector Milne Jill C. was granted 1,262 shares, increasing direct ownership by 8% to 16,644 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Stonehouse Jon P was granted 631 shares, increasing direct ownership by 0.05% to 1,324,481 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Mckee Amy E was granted 631 shares, increasing direct ownership by 2% to 31,883 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Milano Vincent was granted 1,122 shares, increasing direct ownership by 1% to 93,189 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Frank Steven was granted 1,262 shares, increasing direct ownership by 7% to 20,165 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- PRBioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual MeetingRESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio at the Annual Meeting of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Istanbul, Turkey, from June 12-15, 2026. Data include six abstracts featuring new clinical trial and real-world outcomes with ORLADEYO® (berotralstat), the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older, and one abstract featuring clinical trial outcomes with navenibart, a long-acting, monoclonal antibody plasma kallikrein inhib
- INSIDERDirector Mckee Amy E sold $100,285 worth of shares (11,180 units at $8.97), decreasing direct ownership by 26% to 31,252 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERChief Legal Officer Barnes Alane P exercised 62,500 shares at a strike of $5.04 and sold $596,250 worth of shares (62,500 units at $9.54) as part of a pre-agreed trading plan (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- SECSEC Form 144 filed by BioCryst Pharmaceuticals Inc.144 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)
- PRBioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new real-world evidence at the 2026 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference taking place in Philadelphia from May 17–20, 2026. Studies highlight the significant healthcare and quality-of-life burden associated with hereditary angioedema (HAE) in pediatric patients and their caregivers, demonstrating persistent unmet needs and the importance of optimized disease management to reduce healthcare utilization. Underscoring the role of outcomes research in rare diseases, the research draws on large
- SECSEC Form SCHEDULE 13G filed by BioCryst Pharmaceuticals Inc.SCHEDULE 13G - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)
- SECSEC Form 10-Q filed by BioCryst Pharmaceuticals Inc.10-Q - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)
- SECBioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)
- PRBioCryst Reports First Quarter 2026 Financial Results and Provides Business Update— Q1 2026 ORLADEYO® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) — — Announced licensing agreement for European commercial rights to navenibart for $70M upfront and milestone payments up to $275M — RESEARCH TRIANGLE PARK, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today reported financial results for the quarter ended March 31, 2026, and provided a business update. "We began 2026 with continued strong execution across our business, led by sustained growth of ORLADEYO and solid progress across our pipeline," said Charlie Gayer, President and Chief Executive Officer of BioCryst. "ORLADEYO con
BCRX FAQ
7 questionsWhat does BioCryst Pharmaceuticals Inc. do?
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an...Where does BCRX stock trade?
BioCryst Pharmaceuticals Inc. (BCRX) is listed on NASDAQ.What sector and industry is BCRX in?
BioCryst Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did BioCryst Pharmaceuticals Inc. go public?
BioCryst Pharmaceuticals Inc. (BCRX) completed its IPO in 1994.What are analysts saying about BCRX?
BioCryst Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Evercore ISI: Outperform with a $1700.00 price target on 2026-02-18. Recent price targets range from $800.00 to $3000.00.What companies are similar to BCRX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare BCRX side-by-side with any of them on Quantisnow.How can I track BCRX on Quantisnow?
Quantisnow aggregates BioCryst Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BCRX to receive live email and push alerts on every new disclosure.